Sahra Ali

1.3k total citations
17 papers, 637 citations indexed

About

Sahra Ali is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Sahra Ali has authored 17 papers receiving a total of 637 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 7 papers in Genetics and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Sahra Ali's work include Acute Myeloid Leukemia Research (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Sahra Ali is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Sahra Ali collaborates with scholars based in United Kingdom, Denmark and United States. Sahra Ali's co-authors include D. Hensgen, Muthucumaru Maheswaran, Howard Jay Siegel, Shoukat Ali, Steven Knapper, Claire Harrison, Adam J. Mead, Nigel H. Russell, Mary Frances McMullin and Robert K. Hills and has published in prestigious journals such as Blood, British Journal of Haematology and Leukemia.

In The Last Decade

Sahra Ali

17 papers receiving 624 citations

Peers

Sahra Ali

HEMAT

GENET

CNC

Diana Quinlan Canada

John Fisher United States

Ji Hyung Hong South Korea

Neeraj Saini United States

Michael Williams United Kingdom

Athanasios Papadopoulos Greece

Kartik Anand United States

Bernhard Berger Germany

Matthew Poole United Kingdom

Konstantinos Oikonomou Greece

Diana Quinlan Canada

Sahra Ali

655 ×2.5

HEMAT

71 ×0.4

GENET

87 ×0.6

CNC

57 ×0.4

39 ×0.3

Citations per year, relative to Sahra Ali Sahra Ali (= 1×) peers Diana Quinlan

Countries citing papers authored by Sahra Ali

Since Specialization

Citations

This map shows the geographic impact of Sahra Ali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sahra Ali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sahra Ali more than expected).

Fields of papers citing papers by Sahra Ali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sahra Ali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sahra Ali. The network helps show where Sahra Ali may publish in the future.

Co-authorship network of co-authors of Sahra Ali

This figure shows the co-authorship network connecting the top 25 collaborators of Sahra Ali. A scholar is included among the top collaborators of Sahra Ali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sahra Ali. Sahra Ali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Russell, Nigel H., Robert K. Hills, Lars Kjeldsen, et al.. (2022). A randomised comparison of FLAG‐Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. British Journal of Haematology. 198(3). 528–534. 1 indexed citations

Harrington, Patrick, Claire Harrison, Richard Dillon, et al.. (2021). Evidence of robust memory T‐cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). British Journal of Haematology. 193(4). 692–696. 5 indexed citations

Moonim, Mufaddal, Deepti Radia, Natalia Curto‐García, et al.. (2021). Clinicopathological characterisation of myeloproliferative neoplasm‐unclassifiable (MPN‐U): a retrospective analysis from a large UK tertiary referral centre. British Journal of Haematology. 193(4). 792–797. 7 indexed citations

Ali, Sahra, Dominik Karres, Justin L. Hay, et al.. (2019). The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia. The Oncologist. 24(5). e171–e179. 27 indexed citations

McMullin, Mary Frances, Adam J. Mead, Sahra Ali, et al.. (2018). A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis. British Journal of Haematology. 184(2). 161–175. 70 indexed citations

Butt, Nauman M., Jonathan Lambert, Sahra Ali, et al.. (2017). Guideline for the investigation and management of eosinophilia. British Journal of Haematology. 176(4). 553–572. 83 indexed citations

Burnett, Alan K., Nigel H. Russell, Robert K. Hills, et al.. (2016). A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia. 31(2). 310–317. 17 indexed citations

Ali, Sahra, Gail Jones, Dominic Culligan, et al.. (2015). Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. British Journal of Haematology. 170(4). 487–495. 32 indexed citations

Mead, Adam J., Dragana Milojković, Steven Knapper, et al.. (2015). Response to ruxolitinib in patients with intermediate‐1–, intermediate‐2–, and high‐risk myelofibrosis: results of the UK ROBUST Trial. British Journal of Haematology. 170(1). 29–39. 68 indexed citations

10.

Mead, Adam J., Dragana Milojković, Steven Knapper, et al.. (2013). Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial. Blood. 122(21). 2826–2826. 5 indexed citations

11.

Burnett, Alan K., Nigel H. Russell, Ann E. Hunter, et al.. (2013). Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 122(8). 1384–1394. 99 indexed citations

12.

Madden, Leigh A., et al.. (2012). Increased inducible heat shock protein 72 expression associated with PBMC isolated from patients with haematological tumours. Scandinavian Journal of Clinical and Laboratory Investigation. 72(5). 380–386. 1 indexed citations

13.

Burnett, Alan K., Nigel H. Russell, Mary Frances McMullin, et al.. (2012). A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. Blood. 120(21). 889–889. 8 indexed citations

14.

Winkelmann, Nils, Claire Hidalgo-Curtis, Katherine Waghorn, et al.. (2012). RecurrentCEP85L–PDGFRBfusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia. Leukemia & lymphoma. 54(7). 1527–1531. 6 indexed citations

15.

Burnett, Alan K., Robert K. Hills, Ann E. Hunter, et al.. (2011). The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial. Blood. 118(21). 582–582. 18 indexed citations

16.

Watson, James T., et al.. (2006). Inhaled nitrous oxide (Entonox) as a short acting sedative during bone marrow examination. Clinical & Laboratory Haematology. 28(5). 321–324. 23 indexed citations

17.

Ali, Shoukat, Howard Jay Siegel, Muthucumaru Maheswaran, D. Hensgen, & Sahra Ali. (2000). Representing Task and Machine Heterogeneities for Heterogeneous Computing Systems. Journal of Applied Science and Engineering. 3(3). 195–207. 167 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact